The National Times - Booming markets propel Hong Kong exchange's profits to record high

Booming markets propel Hong Kong exchange's profits to record high


Booming markets propel Hong Kong exchange's profits to record high
Booming markets propel Hong Kong exchange's profits to record high / Photo: © AFP

Hong Kong's stock exchange reported record profits for the second consecutive year on Thursday, after the finance hub topped the global rankings for initial public offerings in 2025.

Change text size:

Profit attributable to shareholders rose 36 percent to US$2.3 billion, while total revenue and other income jumped 30 percent to also hit a peak of US$3.7 billion.

Core business revenue climbed 32 percent from the previous year, thanks to increases in trading and clearing fees driven by record volumes across capital markets.

Hong Kong Exchanges and Clearing (HKEx) chairman Carlson Tong said the performance was driven by "strong interest and increasing participation of international and Chinese Mainland investors, amid the ongoing dynamic macro backdrop".

"In 2025, HKEx reinforced its role as a global superconnector, regained its position as the world's leading venue for IPOs and set new trading as well as financial performance records," chief executive Bonnie Chan said.

The firm expects volatility to "persist amid the prevailing macro landscape in 2026", she added.

But she said there was cause for optimism in capital markets as global investors seek diversification and risk management opportunities in Asian and Chinese assets.

HKEx's net investment income is expected to be affected in part by interest rate movement and the redemptions from the external portfolio, Herbert Hui, the exchange's chief financial officer, said Thursday.

- Behind the surge -

Hong Kong's IPO market welcomed 119 new listings and raised a total of US$36.7 billion in 2025, a 226 percent year-over-year increase.

Dozens of companies from China piled into the city last year to raise overseas capital thanks to policy support from Beijing and optimised listing rules by Hong Kong regulators.

The renewed interest in Chinese assets is partly because investors are seeking alternatives outside of the US market and are realising "that the performance of some sectors in China aren't as bad as the feeble wider economy suggest", China-focused economist Kelvin Lam told AFP.

But over exposure to Chinese companies may pose potential risk to Hong Kong's equity market, as they "can be volatile at times through policy and regulatory changes, sometimes not very transparent," said Lam, who works for Pantheon Macroeconomics.

The exchange operator is processing more than 400 listing applications, HKEx's database shows.

Amid the surge, Hong Kong's market regulator, the Securities and Futures Commission (SFC), said in late January it had directed 13 IPO sponsors to conduct internal reviews to "rectify serious deficiencies" in preparing listing documents.

The related behaviours also include sponsors' misconduct and significant mismanagement of resources.

The contacted sponsors are handling 70 percent of IPO applications in Hong Kong.

Earlier this month, exchange head Bonnie Chan told reporters the review request was a "friendly reminder" from the regulators.

She said Thursday that HKEx will continue to roll out listing rules to "support the development of the real economy".

HKEx is also dedicated to improving its market's structure and efficiency, including shortening stock clearing time, she said.

She added the bourse operator would "carefully consider" market calls to broaden the scope of confidential IPO filings. She did not provide details.

In his annual budget on Wednesday, the city's finance chief Paul Chan said the exchange would continue to explore establishing a multi‑asset post‑trade securities platform to cover China and Hong Kong equity and debt markets.

Shares in HKEx were up 0.78 percent on Thursday.

C.Bell--TNT

Featured

The "Everlasting Battery" Inside Your Joints:UConn Professor's Self-Powered Healing Material just Got Acquired

A material that turns your own movement into medicine has just landed a corporate home. PetVivo Holdings (OTCQX: PETV), a veterinary biotech and biomedical device company focused on treating osteoarthritis in dogs and horses, has acquired PiezoBioMembrane (PBM) — a startup built around a biodegradable implant that generates electricity from the everyday force of a joint in motion, and uses that charge to help regrow cartilage from the inside out. The material is the invention of Thanh Nguyen, a professor of mechanical engineering in UConn's College of Engineering, who founded PBM in 2021 to advance new implementation methods for his work with piezoelectric materials — substances that convert mechanical force into electrical energy. These materials are typically ceramics: hard, brittle, and poorly suited for medical use. But Nguyen's lab developed new forms that are so , flexible, and biodegradable, breaking down naturally within the body over time. wound healing, The materials have already shown strong potential across a range of medical applications, including tissue regeneration, implanted force sensors, and targeted drug delivery in tumor treatment. How It Works biodegradable ultrasound for In the case of arthritis, Nguyen explains, the piezoelectric materials function as an off-the-shelf product that can be implanted or injected directly into the ailing joint — with no drugs, chemicals, or cells required. The everyday force exerted on the joint generates a small electrical charge, which helps regrow healthy cartilage, mimicking the body's natural use of electricity to regenerate tissue. "The body can be electrically stimulated to regrow," Nguyen says. PBM's materials "act like a battery — an everlasting battery that works whenever there is a force applied, and vanishes safely inside the body over time." PetVivo's Vision for the Acquisition PetVivo Holdings CEO John Lai expressed enthusiasm for the merger's potential to improve the lives of companion animals globally. "PBM has developed a compelling functional biomaterials platform with the potential to support the development of multiple medical device and therapeutic product lines across both human and animal health markets," Lai said in a press release. "By combining PBM's scientific innovation with PetVivo's product development capabilities, commercialization experience, regulatory expertise, and public company infrastructure, we believe we can accelerate theadvancement of technologies that may serve as the foundation for numerous future products and strategic opportunities." For Nguyen, the deal is a chance to scale technology that could eventually benefit both animals and people. "PetVivo is an animal health company, but they do have a big passion: pushing the technology towards clinical trials for human use," Nguyen says. "That aligned perfectly with my passion for developing technology that has an impact on human life. That is why I am excited about this merger, which facilitates my passion." A Track Record of Innovation Nguyen's research sits at the intersection of medicine, micro/nanotechnology, and biomaterials. His inventions have earned him publications in prominent scientific journals and media coverage from outlets including NPR. Nguyen founded PBM during the COVID-19 pandemic, a er realizing the material he had developed could be used to create an especially effective, biodegradable face mask — one where the mechanical force of breathing generated an electrical charge that provided an extra layer of protection against viruses. PBM is not Nguyen's only venture in the acquisition pipeline. His other startup, Single-Time Microneedles (STM), is also currently undergoing an acquisition process. STM has pioneered stable, efficient vaccine delivery technology in the form of an adhesive patch. shelfNguyen's focus on biodegradable materials has translated into a remarkably diverse range of medical applications. He has received five R01 grants from the National Institutes of Health (NIH) supporting research in cartilage regeneration, bone regeneration, HIV antibody delivery systems, and biodegradable ultrasound technology to boost the effectiveness of chemotherapy for brain cancer. "Whatever we are working on, we want to show that it works very well in vitro and in vivo," Nguyen says. "Then, when we are at the point of commercialization, we set up a startup or license the technology — or maybe team up with an industry partner." Thanh Nguyen is a professor of mechanical engineering in UConn's College of Engineering. (Courtesy of Thanh Nguyen

Octrado introduces its proprietary trading offering: "Your Skill. Our Capital"

Infrastructure, transparent rules and clear legal boundaries positioned as the core of the funded-account model

Could gas prices return to 2022 highs on US-Iran war?

European gas prices have more than doubled owing to the US-Iran war, just as Europe needs to replenish its reserves ahead of winter.

CapTLX Expands Institutional-Oriented Platform for Access to U.S. Capital Markets

CapTLX, the securities trading and investment platform operated by CHAINLION TECH LTD, today announced the continued expansion of its technology infrastructure for qualified investors and institutional market participants seeking structured access to U.S. equity and private capital markets.

Change text size: